Gabriela Sevillano, Ariane Paz Y Miño, María Belén Solís, Juan Pablo Vaca, Camilo Zurita-Salinas, Jeannete Zurita
{"title":"First Report of Antibiotic Resistance Markers <i>cfi</i>A and <i>nim</i> Among <i>Bacteroides fragilis</i> Group Strains in Ecuadorian Patients.","authors":"Gabriela Sevillano, Ariane Paz Y Miño, María Belén Solís, Juan Pablo Vaca, Camilo Zurita-Salinas, Jeannete Zurita","doi":"10.1089/mdr.2023.0125","DOIUrl":null,"url":null,"abstract":"<p><p>In recent years, increasing resistance of <i>Bacteroides fragilis</i> to several antibiotics has been reported in different countries. The aim of this study was to evaluate the antibiotic resistance profiles of <i>Bacteroides</i> spp. isolated from clinical samples by phenotypic and molecular methods. A total of 40 nonrepetitive isolates of the <i>B. fragilis</i> group were studied from 2018 to 2019. The species was identified by API 20A system. The minimum inhibitory concentrations (MICs) were determined by Sensititre anaerobe MIC plate. The presence of the <i>nim</i> and <i>cfiA</i> genes was checked by conventional PCR. The association between genes and insertion sequence (IS) was performed by whole genome sequencing. Eleven isolates were categorized as metronidazole-resistant and only 2 isolates harbored the <i>nim</i> gene. Five isolates were imipenem-resistant, but <i>cfiA</i> gene was detected in two isolates. <i>cfi</i>A gene was closely related to the <i>cfi</i>A-4 allele and associated with IS614B. The <i>nim</i> gene was not related to any <i>nim</i> gene type and was considered a new variant named <i>nim</i>L. IS612 was found upstream of <i>nim</i>L gene. In view of the scarcity of data on <i>B. fragilis</i>, there is a need to surveil antibiotic resistance levels and molecular mechanisms to implement better antimicrobial therapies against this important group of bacteria.</p>","PeriodicalId":18701,"journal":{"name":"Microbial drug resistance","volume":" ","pages":"533-539"},"PeriodicalIF":2.3000,"publicationDate":"2023-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Microbial drug resistance","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1089/mdr.2023.0125","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2023/9/21 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"INFECTIOUS DISEASES","Score":null,"Total":0}
引用次数: 0
Abstract
In recent years, increasing resistance of Bacteroides fragilis to several antibiotics has been reported in different countries. The aim of this study was to evaluate the antibiotic resistance profiles of Bacteroides spp. isolated from clinical samples by phenotypic and molecular methods. A total of 40 nonrepetitive isolates of the B. fragilis group were studied from 2018 to 2019. The species was identified by API 20A system. The minimum inhibitory concentrations (MICs) were determined by Sensititre anaerobe MIC plate. The presence of the nim and cfiA genes was checked by conventional PCR. The association between genes and insertion sequence (IS) was performed by whole genome sequencing. Eleven isolates were categorized as metronidazole-resistant and only 2 isolates harbored the nim gene. Five isolates were imipenem-resistant, but cfiA gene was detected in two isolates. cfiA gene was closely related to the cfiA-4 allele and associated with IS614B. The nim gene was not related to any nim gene type and was considered a new variant named nimL. IS612 was found upstream of nimL gene. In view of the scarcity of data on B. fragilis, there is a need to surveil antibiotic resistance levels and molecular mechanisms to implement better antimicrobial therapies against this important group of bacteria.
期刊介绍:
Microbial Drug Resistance (MDR) is an international, peer-reviewed journal that covers the global spread and threat of multi-drug resistant clones of major pathogens that are widely documented in hospitals and the scientific community. The Journal addresses the serious challenges of trying to decipher the molecular mechanisms of drug resistance. MDR provides a multidisciplinary forum for peer-reviewed original publications as well as topical reviews and special reports.
MDR coverage includes:
Molecular biology of resistance mechanisms
Virulence genes and disease
Molecular epidemiology
Drug design
Infection control.